EPO and stage 5 chronic kidney disease: This study suggests that iron replacement is associated with reduction in platelet counts in iron deficient ND-CKD patients independent of ESA use and extends the observation of Eschbach’s study [33], where it was noted that almost half of their 333 study patients developed iron deficiency with platelet counts increasing following erythropoietin administration to anemic end-stage renal disease patients.